ACTI Active Biotech AB

Number of shares and votes in Active Biotech

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024).

Today, the last trading day of the month, there are in total 217,971,720 shares and votes in Active Biotech.

For further information, please contact:

Hans Kolam, CFO

Tel: +46 (0)46 19 20 44

E-mail:

Active Biotech AB

P.O. Box 724, SE-220 07 Lund, Sweden

Phone +46 (0)46 19 20 00



About Active Biotech

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase I/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021. Please visit for more information.

Active Biotech is required to publish the information contained in this press release in accordance with the Financial Instruments Trading Act. This information was provided to the media for publication at 08.30 am CET on March 31, 2021.

Attachment



EN
31/03/2021

Underlying

ACTIActive Biotech AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Active Biotech AB

 PRESS RELEASE
Free
ACTI Active Biotech ...

Successful completion of the first stage of the phase IIa clinical tri...

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In th...

June 1, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

Det första steget av den kliniska fas IIa studien med naptumomab i kom...

Det första steget av den kliniska fas IIa studien med naptumomab i kombination med docetaxel har framgångsrikt slutförts och rekryteringen till andra steget av studien pågår Lund, 1 juni 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och dess partner NeoTX tillkännager idag det framgångsrika slutförandet av det första steget av en adaptiv (Simon 2 stage) klinisk fas IIa studie med naptumomab estafenatox (NAP, naptumomab), i kombination med docetaxel i patienter med avancerad icke-småcellig lungcancer (NSCLC) som tidigare har behandlats med kemoterapi och checkpointhämmare  (CPI). I studien ...

June 1, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

Annual General Meeting of Active Biotech AB

Annual General Meeting of Active Biotech AB The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2021, and that the Company’s accumulated loss shall be carried forward. The members of the Board and the CEO were discharged from liability with respect to their manag...

May 19, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

Årsstämma i Active Biotech AB

Årsstämma i Active Biotech AB Active Biotechs årsstämma hölls den 19 maj 2022. Mot bakgrund av coronaviruset genomfördes årsstämman med poströstning, utan fysiskt deltagande. Följande huvudsakliga beslut fattades. I enlighet med styrelsens förslag beslutades att ingen utdelning skulle lämnas för räkenskapsåret 2021 och att bolagets ansamlade förlust skulle balanseras i ny räkning. Styrelsens ledamöter och verkställande direktören beviljades ansvarsfrihet för 2021 års förvaltning. I enlighet med valberedningens förslag omvaldes styrelseledamöterna Michael Shalmi, Uli Hack...

May 19, 2022 1 EN
 PRESS RELEASE
Free
ACTI Active Biotech ...

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis   Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of  tasquinimod in thi...

May 18, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch